EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review

Aaron D Besterman, Shafali S Jeste iD

European Child & Adolescent Psychiatry · 2023-03 · 32 (3) · 527-531

DOI: 10.1007/s00787-021-01883-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Child & Adolescent Psychiatry, online erschienen am 05.10.2021. Verfasst von Aaron D Besterman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of California San Diego, San Diego, CA, USA. abesterman@health.ucsd.edu. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Neurodevelopmental Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, national institute of general medical sciences, savant fellowship in neurodevelopmental genetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insomnia is a common, impairing, and difficult-to-treat comorbidity in children with neurodevelopmental disorders (NDDs). Behavioral interventions can be challenging because of developmental and behavioral features that interfere with treatment. Medication management also can be difficult due to a high burden of side effects, a high rate of paradoxical responses, and frequent treatment resistance. Therefore, new treatment options for insomnia in children with NDDs are needed. Dual orexin receptor antagonists (DORAs) are a relatively new class of pharmacotherapeutics that induce sleep by inhibiting the orexin signaling pathway. To date, there is little safety or efficacy data on the use of DORAs in children with NDDs. We present four patients with NDDs and insomnia that we treated with the DORA, suvorexant. We found that patients had a wide range of responses, with one patient displaying a robust improvement in sleep onset and maintenance, while another had significant improvement in insomnia symptoms on combination therapy with trazodone. Our final two patients had mild or no benefit from suvorexant therapy. Further research is necessary to establish the safety and efficacy of DORAs in this population and to identify predictive factors, such as specific neurogenetic diagnoses or clinical features, of a positive treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersNeurodevelopmental DisordersChildHumansAdolescentOrexin Receptor AntagonistsSleepResearch

Stichwörter der Autor:innen

Dual orexin receptor antagonistsInsomniaNeurodevelopmental disordersSleep disorders

Substanzen

Orexin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Psychiatry, University of California San Diego, San Diego, CA, USA. abesterman@health.ucsd.edu.
  • Rady Children's Hospital of San Diego, 3020 Children's Way, San Diego, CA, 92123, USA. abesterman@health.ucsd.edu.
  • Rady Children's Institute for Genomic Medicine, San Diego, CA, USA. abesterman@health.ucsd.edu.
  • Semel Institute for Neuroscience and Human Behavior, University of California Los Angles, Los Angeles, CA, USA. abesterman@health.ucsd.edu.
  • Semel Institute for Neuroscience and Human Behavior, University of California Los Angles, Los Angeles, CA, USA.
  • Division of Child Neurology, Department of Pediatrics, UCLA David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

ORCID-Profile: Shafali S Jeste

Förderung

  • NIGMS NIH HHS
  • national institute of general medical sciences
  • savant fellowship in neurodevelopmental genetics

Zitieren

APA

Besterman, A. D., & Jeste, S. S. (2023). Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review. European Child & Adolescent Psychiatry, 32(3), 527-531. https://doi.org/10.1007/s00787-021-01883-7

Vancouver

Besterman AD, Jeste SS. Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review. European Child & Adolescent Psychiatry. 2023;32(3):527-531. doi:10.1007/s00787-021-01883-7

BibTeX
@article{Besterman2023,
  author = {Besterman, Aaron D and Jeste, Shafali S},
  title = {Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review},
  journal = {European Child & Adolescent Psychiatry},
  year = {2023},
  volume = {32},
  number = {3},
  pages = {527--531},
  doi = {10.1007/s00787-021-01883-7}
}
Kostenlos starten →